BioVolume 3D Subcutaneous tumour imaging

SEE YOUR STUDIES IN 3D

Advancing pre-clinical oncology with thermography and 3D scanning of subcutaneous tumours.

BioVolume 3D tumour model

CAPTURE COMPLEX TUMOUR MORPHOLOGIES

Maybe not these exact images because the ulcerated one is a bit gross for the front page- but it'd be good to have some scans to show off

Complex_tumour_scans.png

BioVolume is the world’s first 3D imaging solution that has been developed in partnership with a leading pharmaceutical company and wider industry for visualising and measuring subcutaneous tumour growth in preclinical oncology research.

It was conceived to enable faster, smarter and more confident decisions to be made in the identification and development of new cancer therapeutics.

 

Used by leading pharma, bioTech and research insitutions including:

Bristol Myer-Squibb BioVolume client
GNF BioVolume client

BENEFITS

BioVolume enables cancer research companies to obtain more accurate, repeatable data than before. Translational science is also improved through data reliability and transparency.

BioVolume repeatability

REPEATABILITY

By significantly reducing

inter-operator variability across studies BioVolume can improve repeatability, removing the reliance on a single operator to complete a study.

BioVolume scientific confidence

SCIENTIFIC CONFIDENCE

With 3D imaging and thermography of each rodent tumour 
BioVolume's algorithmic
approach to segmentation
and measurement ensures
consistency in output.

BioVolume traceability

TRACEABILITY

BioVolume's secure cloud-based platform ensures all data is a captured, secured and available for review, offering full transparency in study data collection and analysis.  

 
BioVolume 3D and Thermal scanner

LATEST NEWS AND PUBLICATIONS

Stay up to date with  BioVolume. 

In silico modelling demonstrates that user variability during tumor measurement can affect in vivo therapeutic efficacy outcomes
5/4/22, 7:41 AM

We show greater measurement variability results in greater experimental uncertainty, and BioVolume can reduce the chance of a false negative result.

A comparison of tumour volume accuracy taken with Callipers and BioVolume when compared to excised tumour weights
10/11/21, 10:19 AM

A poster exploring how using a BioVolume captured height measurement offers an average volume 8 times closer to the excised weight measurements than callipers.

Creating the digital lab of the future
4/1/21, 1:19 PM

BioVolume is now integrated with the Somark Sensalab benchtop reader for a fully automated identification and capture process

Reducing inter-operator variability poster with GNF
11/16/20, 9:58 AM

A poster publication in partnership with GNF exploring how BioVolume can reduce inter-operator variability in measuring subcutaneous tumours

Optimising Measurement Of Subcutaneous Rodent Leg Tumours
3/25/22, 1:51 PM

Our work with HZDR found measurement variability of rodent leg tumours can be decreased by inoculating tumour high up in the shoulder, and by using BioVolume instead of callipers.

Reducing inter-operator variability when measuring subcutaneous tumours in mice
10/11/21, 9:58 AM

Our preprint publication analysing operator variability of BioVolume vs callipers, and impact on drug efficacy assessment in over 5,000 repeats across 238 studies.

Improving reproducibility through data traceability with St. Jude Children's Research Hospital
3/9/21, 9:27 AM

Data traceability and its contribution to study reproducibility a poster in partnership with St. Jude Children's Research Hospital

PLOS ONE
4/27/20, 1:41 PM

A Publication on an innovative non-invasive technique for subcutaneous tumour measurements

Using calibrated photographic images and thermal data to investigate trends in tumour conditions
10/11/21, 10:34 AM

A poster analysing how structured image and thermal data can be used to identify trends in tumour condition in both the days leading up to, and the days following the point of ulceration.

Can digital innovation solve the reproducibility crisis?
7/12/21, 8:58 AM

Recent analysis has reported irreproducibility rates in pre-clinical research to range from 51%-89%.

BioVolume 2020 webinars
1/14/21, 12:07 PM

Video content of all BioVolume content presented at the 2020 AALAS conference

CONTACT US